APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA) Meeting Abstract

  

Authors:	Tempero, M. A.; Cardin, D. B.; Biankin, A.; Goldstein, D.; Moore, M.; O'Reilly, E. M.; Philip, P. A.; Riess, H.; Macarulla, T.; Yung, L.; Wei, X. Y.; Lu, B.
Abstract Title:	APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA)
Meeting Title:	50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	32
Issue:	15 Suppl.
Meeting Dates:	2014 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2014-05-20
Language:	English
ACCESSION:	WOS:000358613202111
PROVIDER:	wos
DOI:	10.1200/jco.2014.32.15_suppl.TPS4162
Notes:	Meeting Abstract: TPS4162^ -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/81072